Taking 2.5 mg from a 5mg Mounjaro pen: the decision and the facts

Why your starting dose comes in a 5mg pen

Mounjaro (tirzepatide) is made by Eli Lilly and comes in a KwikPen format across six UK-licensed strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The naming of each pen reflects the total medication it holds, not the amount delivered per injection. A 5mg pen is engineered to give precisely four injections of 2.5 mg each. Lilly designed it this way so a single pen lasts two weeks, and a standard four-week pack includes two pens, giving you eight injections in total, all at the same 2.5 mg dose.

There is no syringe work, no splitting of a dose, and no guesswork. You press the button, the pen stops when it has delivered 2.5 mg, and that is that. Store it in the fridge door when you get home and take it out about 30 minutes before your weekly injection so it reaches room temperature, that is the kind of routine detail patients tell us makes early weeks more comfortable.

The 5mg KwikPen page explains the pen's mechanism in more detail, including needle attachment and the audible click that confirms the dose is complete.

The real purpose of the 2.5 mg starting dose

The 2.5 mg dose exists for tolerability, not for weight-loss effect. Tirzepatide is a dual GIP and GLP-1 receptor agonist: it slows gastric emptying and reduces appetite, and those effects can cause nausea, bloating, or digestive discomfort when the body encounters them for the first time. Beginning at a lower exposure gives your system time to adapt, which is why the licensed schedule (described in the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC)) starts here before moving upward in roughly four-week steps.

That framing matters for managing expectations. If you finish your first pen and feel the weight-loss effect has been modest, that is by design. The dose ladder exists to get you to a therapeutic level safely, not to limit the treatment's potential. Your prescriber holds the picture of where your dose is heading and when it is appropriate to move.

For context on what happens when the time does come to increase, this page covers the clinical factors behind moving from 2.5 to 5 mg.

Off-label splitting (and why this page is not about that

Some people search for ways to draw a non-standard dose from a Mounjaro pen) 3.75 mg from a 5mg pen being a common one, and worth addressing plainly. The KwikPen is not designed to deliver partial or intermediate amounts. Attempting to interrupt a dose mid-injection or to draw medication from the cartridge introduces serious risks: inaccurate dosing, contamination, and potential damage to the mechanism. The guidance on any 3.75 mg query from a 5mg pen is consistent: it is not a licensed or recommended approach.

By contrast, taking the full 2.5 mg dose from a 5mg pen is exactly what the pen is made for. There is no modification involved. If a prescriber has written 2.5 mg and you have a 5mg pen, your instructions and your device are aligned. Equally, if you have ever wondered about the mechanics of non-standard dosing from a 7.5 mg pen, the same principle applies, the pen delivers what it is designed to deliver, full stop.

The broader tirzepatide overview sets out the full evidence base and licensed indications for Mounjaro in the UK, which may be useful if you are still weighing up whether treatment is right for you.

Practical questions your prescriber should answer, and where to get them answered

A prescriber's job is to handle the decisions that sit above the mechanical ones: whether 2.5 mg is the right starting point for you specifically, how long you stay there, and what evidence they need before moving you up. If you have a clinical question (about side effects, the injection technique, or timing) that sits outside what the Patient Information Leaflet covers, that goes to your clinical team, not to a forum.

The NHS patient page for tirzepatide on NHS.co.uk is a reliable starting point for common questions on side effects and missed doses. For anything dose-specific, your prescriber is the right person. At nume, a GPhC-registered Independent Prescriber reads every consultation (a real clinician, not an automated system) and is available for aftercare questions seven days a week.

If cost is part of what you are weighing up before committing to treatment, the Mounjaro price comparison page explains how UK private pricing works and what a transparent price should include. The right question is not which clinic is cheapest, but which one is properly regulated and genuinely monitors your progress.